IMMP vs. ARQT, OPK, LQDA, INVA, VRNA, IRWD, BCYC, OCUL, GYRE, and IMNM
Should you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Arcutis Biotherapeutics (ARQT), OPKO Health (OPK), Liquidia (LQDA), Innoviva (INVA), Verona Pharma (VRNA), Ironwood Pharmaceuticals (IRWD), Bicycle Therapeutics (BCYC), Ocular Therapeutix (OCUL), Gyre Therapeutics (GYRE), and Immunome (IMNM). These companies are all part of the "pharmaceutical preparations" industry.
Arcutis Biotherapeutics (NASDAQ:ARQT) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Arcutis Biotherapeutics presently has a consensus target price of $25.38, indicating a potential upside of 193.01%. Immutep has a consensus target price of $8.50, indicating a potential upside of 196.17%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Immutep is more favorable than Arcutis Biotherapeutics.
In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Immutep. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 4 mentions for Immutep. Arcutis Biotherapeutics' average media sentiment score of 1.17 beat Immutep's score of 0.98 indicating that Immutep is being referred to more favorably in the news media.
2.3% of Immutep shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 3.1% of Immutep shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Immutep received 256 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 72.43% of users gave Immutep an outperform vote while only 62.07% of users gave Arcutis Biotherapeutics an outperform vote.
Immutep has lower revenue, but higher earnings than Arcutis Biotherapeutics.
Arcutis Biotherapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.
Immutep has a net margin of 0.00% compared to Immutep's net margin of -204.35%. Arcutis Biotherapeutics' return on equity of 0.00% beat Immutep's return on equity.
Summary
Immutep beats Arcutis Biotherapeutics on 12 of the 16 factors compared between the two stocks.
Get Immutep News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
